Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
0.630 GeneticVariation disease BEFREE FGFR1 CNG (10.7%), FGFR1 mutation (2.7%), FGFR2 mutation (2.7%), FGFR4 mutation (5.3%), and FGFR3 fusion (1.3%) were detected in LSCC specimens by NGS. 27581340 2016
Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
0.630 GeneticVariation disease GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191 2016
Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
0.630 GeneticVariation disease BEFREE FGFR2 and other FGFR kinase family gene alterations have been found in both lung squamous cell carcinoma and lung adenocarcinoma, although mouse models of FGFR-driven lung cancers have not been reported. 25035393 2014
Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
0.630 GeneticVariation disease BEFREE Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. 23786770 2013
Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
0.630 GeneticVariation disease CLINVAR Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. 23786770 2013
Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
0.630 GeneticVariation disease UNIPROT
Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
0.630 CausalMutation disease CGI
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. 31660987 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE EGFR mutation is associatedwith short PFS and the brain is the most common site of distant metastasis in patients with stage III non- squamous cell lung cancer treated with CCRT. 29914238 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE EGFR rs2233947 correlated with lung cancer in males, smokers, and in the squamous cell carcinoma lung cancer subtype (P<0.01). 31518089 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE To analyze the distribution of epidermal growth factor receptor (<i>EGFR</i>) mutations; characterize the clinical and imageological features of lung squamous cell carcinoma (LSCC) in a large population of patients; and assess correlations between clinical and imageological characteristics and clinical outcomes of LSCC patients harboring <i>EGFR</i> mutations. 31695493 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An <i>EGFR</i> Sensitizing Mutation. 31802898 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE More macrophages were found in lung squamous cell carcinoma (LUSC) patients, patients with wild-type EGFR, and smokers than in patients with lung adenocarcinoma (LUAD), patients with EGFR mutations, and non-smokers. 31308749 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE We found EGFR-mutant LUAD showed significantly higher ITHi than KRAS-mutant LUAD/wild-type LUAD (P = 0.03) and numerically higher ITH than LUSC. 30626401 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE Survival analysis found that TP53 and EGFR showed a significant correlation (log rank P = 3e-07 and 0.023) with lung adenocarcinoma and lung squamous cell carcinoma, according to KM analysis. 31544704 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma. 31283542 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE Fourteen epidermal growth factor receptor (EGFR)-mutant LSCC patients treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy were enrolled for validation dataset. 30643941 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE Concurrent inhibition of the PD-1 and epidermal growth factor receptor (EGFR) pathways represents a rational approach to improve responses and delay the onset of treatment resistance in lung SCC. 30808583 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. 30788361 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE A total of 10.5% of the LUSC subgroup had somatic alterations with therapeutic relevance, including in EGFR (2.8%), ALK/ROS1 (1.3%), BRAF (1.5%), and MET amplification or exon 14 skipping (5.1%). 30279110 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE Detection and monitoring of driver mutations by next-generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR-tyrosine kinase inhibitors. 29143497 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE Significant differences in NIC, K values, and calcium content were observed between the EGFR-positive and EGFR-negative groups among patients with SC. 29752156 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE Therefore, we investigated the feasibility of applying this method to mediastinal lymph node metastases in an epidermal growth factor receptor (EGFR)-positive squamous cell carcinoma of the lung. 29856819 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation disease BEFREE The administration of afatinib to Sq patients after selecting patients using the EGFR mutation test based on their underlying pulmonary disease and smoking status would likely result in a population with a greater sensitivity to afatinib. 29446042 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker disease BEFREE Although the majority of these advances took place in the non-squamous histological subtype, therapeutic options for patients diagnosed with advanced squamous cell lung cancer (SqCLC) have been also enriched significantly with the addition of nab-paclitaxel in the conventional chemotherapy; the introduction of necitumumab, afatinib and erlotinib in the inhibition of epidermal growth factor receptor (EGFR) axis and of ramucirumab in the inhibition of VEGF-induced angiogenesis and last with the approvals of nivolumab, pembrolizumab atezolizumab and durvalumab soon in the promising field of immunotherapies. 29862232 2018